XTalks
SEPTEMBER 15, 2020
In addition to the vaccine, the company is also developing an investigational drug called Remygen for the regeneration of endogenous insulin production and to improve hormonal response to hypoglycemia; trials to test the treatment are currently ongoing in patients that have been living with type 1 diabetes for more than five years.
XTalks
AUGUST 17, 2020
Treatment vaccines : these boost the immune system responses to target cells. Immune system modulators (i.e. receptors) of the immune system to enhance, or suppress immune responses. protein-based biologics) : are those which bind to specific components (i.e. Nature by Design. Image from Cue Biopharma.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MAY 16, 2021
KetosisNOW contains clinically relevant amounts of ingredients that fight insulin resistance, inflammation and toxic build up inside the body. You will also see an improvement in your immune. KetosisNOW can help as it targets the problems that cause weight loss resistance. We are confident. We are that confident that KetosisNOW.
The Pharma Data
AUGUST 3, 2021
The trial compared tirzepatide to insulin glargine in adults with type 2 diabetes and increased cardiovascular risk. announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses. 25% $ 2,988.1 $ 2,459.1
The Pharma Data
DECEMBER 31, 2020
“Antibody responses are not likely to be the sole determinant of someone’s outcome,” said Scott Boyd, associate professor of pathology at Stanford. Some of these patients mount a vigorous immune response, and others have a more moderate response. There are also other branches of the immune system involved.
The Pharma Data
APRIL 4, 2023
Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who are not eligible for cisplatin-containing chemotherapy. Withhold KEYTRUDA depending on severity.
The Pharma Data
JULY 23, 2021
Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.
Expert insights. Personalized for you.
103 
Let's personalize your content